{
    "organizations": [],
    "uuid": "9bf480a5c5188c94b80d9d0179fcdbc03fb12019",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-alnylam-announces-ema-acceptance-o/brief-alnylam-announces-ema-acceptance-of-marketing-authorisation-application-for-patisiran-idUSFWN1PK1KR",
    "ord_in_thread": 0,
    "title": "BRIEF-Alnylam Announces EMA Acceptance Of Marketing Authorisation Application For Patisiran",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 25 (Reuters) - Alnylam Pharmaceuticals Inc:\n* ALNYLAM ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORISATION APPLICATION (MAA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS\n* ALNYLAM PHARMACEUTICALS- UK MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY HAS GRANTED DESIGNATION OF PATISIRAN AS A PROMISING INNOVATIVE MEDICINE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-26T05:20:00.000+02:00",
    "crawled": "2018-01-26T21:33:54.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "alnylam",
        "pharmaceutical",
        "inc",
        "alnylam",
        "announces",
        "ema",
        "acceptance",
        "marketing",
        "authorisation",
        "application",
        "maa",
        "patisiran",
        "treatment",
        "hereditary",
        "attr",
        "hattr",
        "amyloidosis",
        "alnylam",
        "uk",
        "medicine",
        "healthcare",
        "product",
        "regulatory",
        "agency",
        "granted",
        "designation",
        "patisiran",
        "promising",
        "innovative",
        "medicine",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}